Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.05.2024 | Case report

Pembrolizumab

Cavitary mycobacterium avium complex-pulmonary disease

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Chi C-Y, et al. Cavitary Mycobacterium avium Complex Lung Disease Developed After Immunotherapy. Archivos de Bronconeumologia 58: 174, No. 2, Feb 2022. Available from: URL: 10.1016/j.arbres.2021.04.014 Chi C-Y, et al. Cavitary Mycobacterium avium Complex Lung Disease Developed After Immunotherapy. Archivos de Bronconeumologia 58: 174, No. 2, Feb 2022. Available from: URL: 10.1016/j.arbres.2021.04.014
Metadaten
Titel
Pembrolizumab
Cavitary mycobacterium avium complex-pulmonary disease
Publikationsdatum
01.05.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-58848-8

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Ibrutinib

Case report

Multipled drugs

Case report

Multiple drugs

Case report

Epinephrine